X
Novo completes major filings for blockbuster hope semaglutide
https://pharmaphorum.com/news/novos-semaglutide-filed-five-key-markets/
Novo Nordisk
Patient death raises concerns over Roche haemophilia drug
Concerns following event on HAVEN1 trial.
Sanofi diabetes combo approved in EU
Drug will compete against Novo Nordisk’s Xultophy.
Pfizer, Novo invest in Swedish patient stratification startup
Funds will go towards development of AMRA’s body composition profiling tool AMRA Profiler.
Digital health round-up – health innovations shine at CES 2017
A round-up of this week’s top digital healthcare news. Marco Ricci reports.
Roche’s haemophilia drug hits phase 3 targets
Roche hopes to take on Novo Nordisk and Shire.
Lilly and Boehringer biosimilar undercuts Lantus by 15%
Sanofi under pressure following long-awaited biosimilar launch.
“I’m going to bring down drug prices” – Trump
President-elect takes swipe at pharma after Time “Person of the Year” accolade.
Cost the barrier, but Novo not giving up on insulin pill, says CEO
Cost of pill will be too much for payers to stomach, says Novo.